Illumina launches research test for HRD

By staff writers

June 22, 2022 -- Illumina on Wednesday announced the launch of a next-generation sequencing (NGS)-based research-use-only test for homologous recombination deficiency that it has developed with Merck.

The test will be made available globally outside the U.S. and Japan and enable researchers to unlock deeper insights about the tumor genome by identifying genetic mutations used in the evaluation of homologous recombination deficiency (HRD), Illumina said.

HRD is a genomic signature produced when cells are unable to effectively repair double-stranded DNA breaks. When this occurs, cells rely on alternative, error-prone DNA repair mechanisms, which may lead to genomic instability and, eventually, tumor formation.

Image courtesy of Illumina.

The assay, known as the TruSight Oncology 500 HRD test, uses Illumina NGS technology and validated HRD technology from Myriad Genetics. It enables labs to accurately detect genomic instability and analyze more than 500 genes simultaneously, including those relevant to HRD status, Illumina said.

"HRD status has emerged as an important biomarker in tumors that harbor high levels of DNA damage, such as ovarian, breast, prostate, and pancreatic cancers," Phil Febbo, MD, chief medical officer at Illumina, said in a statement.

Rady Children’s Institute launches newborn genetic disease screening
Rady Children's Institute for Genomic Medicine (RCIGM) has launched a program that aims to advance newborn screening for treatable genetic diseases through...
FDA warns about Illumina NGS cybersecurity vulnerability
The U.S. Food and Drug Administration (FDA) on Thursday informed laboratory personnel and healthcare providers about a cybersecurity vulnerability affecting...
Illumina wins new indication for TruSight Oncology in Europe
Illumina has received a new pan-cancer companion diagnostic (CDx) indication to the CE Mark for its TruSight Oncology Comprehensive (EU) test kit, which...
Illumina to collaborate with Allegheny Health
Illumina plans to collaborate with Allegheny Health Network on a study regarding the impact on medical care of in-house genomic profiling for cancer patients.
Illumina brings whole-genome sequencing to German hospital
Illumina has signed an agreement with Hannover Medical School in Germany to assess the use of rapid whole-genome sequencing (rWGS) in critically ill children...

Copyright © 2022

Last Updated lo 6/23/2022 6:32:17 AM